A Project to Facilitate the Access to Clinical Trial Data and to Manage its Reuse
The current fragmentation of clinical data in separate repositories makes the return and reuse of clinical trial data particularly complex and challenging.
The IMI project FACILITATE aims to develop an innovative process for the return and reuse of data within an ethical legal framework compliant with the General Data Protection Regulation (GDPR) and recognized as:
- enable access and portability of patient data
- strengthen the role of patients in clinical trial strategy and design
- put patients at the center of the drug development process.
The project brings together stakeholders at all levels in the decision-making chain, including patients, healthcare professionals, software developers, pharma representatives, clinical trial repositories processors and controllers, ethicists, lawyers, and other active regulators. Cittadinanzattiva, thought its EU branch Active Citizenship Network, is officially involved in the FACILITATE Consortium.
To better understand FACILITATE’s innovative approach to returning data to trial participants, join our webinar, register now!
When: January 27, 2023, at 4 pm-5 pm CEST
Duration: 45 Minutes + 15 Minutes discussion
Registration Form: link
For whom: All those interested and involved in some way in clinical trials and the management of their data: first of all patients and their associations, clinicians, pharma industries, regulatory authorities etc.
Why: FACILITATE promotion to engage stakeholders and the public: Join our pool of Stekholders here
- Luca Pani (Coordinator, UNIMORE)
- Véronique Poinsot (Project leader, Sanofi)
- Johanna Blom (Vice-coordinator, UNIMORE)
- Nadir Ammour (Sanofi)
- Pauline Granger (Sanofi)
- Ciara Staunton (EURAC)
- Deborah Mascalzoni (EURAC)
- Daniela Quaggia (ACN)
- Nuala Ryan (Takeda)
For further information please contact:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034366.
The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.